Awad J A, Morrow J D, Roberts L J
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6602.
J Chromatogr. 1993 Jul 23;617(1):124-8. doi: 10.1016/0378-4347(93)80430-c.
The symptoms and hemodynamic alterations that accompany systemic mast cell activation have been attributed in large part to an excessive release of prostaglandin D2 (PGD2). Further, PGD2 has been implicated in the adverse effects of some pharmacologic agents (e.g. nicotinic acid). Quantitation of the major urinary metabolite of PGD2 has been invaluable in elucidating a role for PGD2 in these clinical entities and in the biochemical diagnosis of the disease systemic mastocytosis. However, the stable-isotope mass spectrometric assay originally developed for quantification of this metabolite has been too cumbersome for routine use. We now report improvements in the assay that greatly increase its utility by shortening sample processing and eliminating the need for purification using thin-layer chromatography. The precision and accuracy of the modified assay was evaluated and found to be comparable with the previously described assay. These modifications potentially allow wider use of the assay to explore the role of PGD2 in human disease and in the routine biochemical diagnosis of systemic mastocytosis and other disorders of mast cell activation.
全身性肥大细胞活化所伴随的症状和血流动力学改变，在很大程度上归因于前列腺素D2（PGD2）的过度释放。此外，PGD2与某些药物（如烟酸）的不良反应有关。PGD2主要尿代谢产物的定量分析，对于阐明PGD2在这些临床病症中的作用以及系统性肥大细胞增多症的生化诊断具有重要价值。然而，最初开发用于定量该代谢产物的稳定同位素质谱分析法对于常规使用来说过于繁琐。我们现在报告该分析方法的改进，通过缩短样品处理时间并消除使用薄层色谱法进行纯化的需求，大大提高了其实用性。对改进后的分析方法的精密度和准确性进行了评估，发现与先前描述的方法相当。这些改进可能使该分析方法更广泛地用于探索PGD2在人类疾病中的作用以及系统性肥大细胞增多症和其他肥大细胞活化障碍的常规生化诊断。
